Select octogenarians with stage IIIa non-small cell lung cancer can benefit from trimodality therapy.
CR, chemoradiotherapy
NCDB, National Cancer Database
NSCLC
NSCLC, non–small cell lung cancer
TM, trimodality therapy
octogenarian
stage IIIa
trimodality therapy
Journal
JTCVS open
ISSN: 2666-2736
Titre abrégé: JTCVS Open
Pays: Netherlands
ID NLM: 101768541
Informations de publication
Date de publication:
Jun 2022
Jun 2022
Historique:
received:
24
05
2021
accepted:
13
01
2022
entrez:
25
8
2022
pubmed:
26
8
2022
medline:
26
8
2022
Statut:
epublish
Résumé
Currently, more than 36% of patients diagnosed with lung cancer are 75 years of age or older. Management of stage IIIA cancer is variable, especially for octogenarians who might not be offered surgery because of questionable benefit. In this study we investigated the outcomes of definitive chemoradiotherapy (CR) and trimodality therapy (TM) management (CR and surgery) for clinical stage IIIA non-small cell lung cancer (NSCLC) in patients 80 years of age or older. The National Cancer Data Base was queried for stage IIIA NSCLC in patients 80 years of age or older between 2004 and 2015. Patients were divided according to treatment type: definitive CR and TM. Patient demographic characteristics, facility type, Charlson-Deyo score, final tumor pathology, and survival data were extracted. Univariate analysis was performed, followed by 3:1 propensity matching to analyze overall survival differences. Unadjusted and adjusted Kaplan-Meier survival analyses were performed. From the database, 6048 CR and 190 TM octogenarians were identified. Patients in the TM group were younger (82 years old [TM] vs 83 years old [CR]; Selected elderly patients with stage IIIa NSCLC can benefit from an aggressive TM approach.
Identifiants
pubmed: 36004217
doi: 10.1016/j.xjon.2022.01.022
pii: S2666-2736(22)00070-5
pmc: PMC9390188
doi:
Types de publication
Journal Article
Langues
eng
Pagination
395-403Informations de copyright
© 2022 The Author(s).
Références
J Thorac Cardiovasc Surg. 2021 Mar;161(3):822-832.e6
pubmed: 33451846
Can Respir J. 2017;2017:6294895
pubmed: 28270738
Ann Surg Oncol. 2008 Mar;15(3):683-90
pubmed: 18183467
Oncologist. 2020 Jun;25(6):e964-e975
pubmed: 31943520
Ann Thorac Surg. 2015 Dec;100(6):2026-32; discussion 2032
pubmed: 26319488
J Thorac Oncol. 2014 May;9(5):612-21
pubmed: 24722151
Ann Thorac Surg. 2016 Sep;102(3):962-970
pubmed: 27234579
J Thorac Cardiovasc Surg. 2019 Apr;157(4):1660-1667
pubmed: 30711277
Ann Thorac Surg. 2017 Aug;104(2):395-403
pubmed: 28527969
Ann Thorac Surg. 2021 Jul 30;:
pubmed: 34339672
Natl Vital Stat Rep. 2020 Nov;69(12):1-45
pubmed: 33270553
J Thorac Dis. 2019 Jun;11(6):2420-2430
pubmed: 31372279
Semin Thorac Cardiovasc Surg. 2020 Spring;32(1):153-159
pubmed: 31220530
Eur J Cardiothorac Surg. 2021 Jul 14;60(1):81-88
pubmed: 33661301
J Thorac Cardiovasc Surg. 2010 Aug;140(2):356-63
pubmed: 20381815
Ann Thorac Surg. 2020 May;109(5):1503-1511
pubmed: 31733187
J Thorac Oncol. 2021 May;16(5):860-867
pubmed: 33476803
Thorac Surg Clin. 2016 Aug;26(3):271-85
pubmed: 27427522
Lung Cancer. 2018 Feb;116:55-61
pubmed: 29413051
Ann Thorac Surg. 2014 Aug;98(2):424-32; discussion 432
pubmed: 24929895
Ann Thorac Surg. 2021 Nov;112(5):1600-1608
pubmed: 33321089
J Thorac Oncol. 2013 Jun;8(6):744-52
pubmed: 23571473